Verastem's partner reports 68.8% ORR for VS-7375 in KRAS G12D NSCLC at RP2D

Verastem, Inc.

ORR of 68.8% (11/16) and DCR of 93.8% (15/16) at recommended Phase 2 dose of 600 mg QD in NSCLC patients.
Across all dose levels, ORR 57.7% (15/26) and DCR 88.5% (23/26) in evaluable advanced NSCLC patients.
Safety profile: TRAEs in 27.5% (39/142), Grade≥3 SAEs in 7.7% (11/142); no TRAE-related deaths; 6 discontinuations.
Data to be presented in mini oral at IASLC WCLC on Sept 7, 2025; builds on prior ASCO ORR of 42% (n=12).

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.